267 related articles for article (PubMed ID: 18060370)
1. Recent discoveries in the genetics of melanoma and their therapeutic implications.
Marquette A; Bagot M; Bensussan A; Dumaz N
Arch Immunol Ther Exp (Warsz); 2007; 55(6):363-72. PubMed ID: 18060370
[TBL] [Abstract][Full Text] [Related]
2. [Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].
Favre G
Bull Acad Natl Med; 2014 Feb; 198(2):321-36; discussion 337-8. PubMed ID: 26263707
[TBL] [Abstract][Full Text] [Related]
3. Active surrender.
Collisson EA
Pigment Cell Melanoma Res; 2012 May; 25(3):292-3. PubMed ID: 22629566
[No Abstract] [Full Text] [Related]
4. [Genetic diversity and immunological characteristics of malignant melanoma: the therapeutic spectrum].
Doma V; Gulya E
Orv Hetil; 2015 Apr; 156(15):583-91. PubMed ID: 25845317
[TBL] [Abstract][Full Text] [Related]
5. Ras, Raf, and MAP kinase in melanoma.
Solus JF; Kraft S
Adv Anat Pathol; 2013 Jul; 20(4):217-26. PubMed ID: 23752084
[TBL] [Abstract][Full Text] [Related]
6. KIT and Melanoma: Biological Insights and Clinical Implications.
Pham DDM; Guhan S; Tsao H
Yonsei Med J; 2020 Jul; 61(7):562-571. PubMed ID: 32608199
[TBL] [Abstract][Full Text] [Related]
7. Parsing out the complexity of RAF inhibitor resistance.
McMahon M
Pigment Cell Melanoma Res; 2011 Apr; 24(2):361-5. PubMed ID: 21392366
[No Abstract] [Full Text] [Related]
8. Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling.
Paluncic J; Kovacevic Z; Jansson PJ; Kalinowski D; Merlot AM; Huang ML; Lok HC; Sahni S; Lane DJ; Richardson DR
Biochim Biophys Acta; 2016 Apr; 1863(4):770-84. PubMed ID: 26844774
[TBL] [Abstract][Full Text] [Related]
9. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
[TBL] [Abstract][Full Text] [Related]
10. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.
Miller DM; Flaherty KT; Tsao H
Semin Cutan Med Surg; 2014 Jun; 33(2):60-7. PubMed ID: 25085663
[TBL] [Abstract][Full Text] [Related]
11. Molecular biology of melanoma.
Swick JM; Maize JC
J Am Acad Dermatol; 2012 Nov; 67(5):1049-54. PubMed ID: 22459362
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic approaches in Melanoma - a paradigm for personalized medicine].
Dummer R; Goldinger S; Rinderknecht J; Eggmann N; Felderer L; Braun R; French LE
Praxis (Bern 1994); 2012 Jul; 101(15):955-9. PubMed ID: 22811327
[TBL] [Abstract][Full Text] [Related]
13. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathogenesis of cutaneous melanocytic neoplasms.
Ibrahim N; Haluska FG
Annu Rev Pathol; 2009; 4():551-79. PubMed ID: 19400696
[TBL] [Abstract][Full Text] [Related]
15. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of melanoma.
Pickert A
Cutis; 2012 Mar; 89(3):E1-4. PubMed ID: 23961517
[No Abstract] [Full Text] [Related]
17. Targeting oncogenic drivers and the immune system in melanoma.
McArthur GA; Ribas A
J Clin Oncol; 2013 Feb; 31(4):499-506. PubMed ID: 23248252
[TBL] [Abstract][Full Text] [Related]
18. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells.
Kong Y; Kumar SM; Xu X
Arch Pathol Lab Med; 2010 Dec; 134(12):1740-9. PubMed ID: 21128770
[TBL] [Abstract][Full Text] [Related]
20. c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes.
Monsel G; Ortonne N; Bagot M; Bensussan A; Dumaz N
Oncogene; 2010 Jan; 29(2):227-36. PubMed ID: 19802003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]